Clinical trials of targeted alpha therapy for cancer

Reviews on Recent Clinical Trials

Volumn 3, Issue 3, 2008, Pages 185-191

  Allen, Barry J ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

Cancer cells; Leukaemia; Lymphoma; Micrometastases; Pancreatic cancer; Radioisotopes; Targeted Alpha Therapy

Indexed keywords

ACTINIUM 225; ASTATINE 211; BISMUTH 212; BISMUTH 213; CYTARABINE; GADOLINIUM; IODINE 123; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 81C6 AT 211; MONOCLONAL ANTIBODY 9.2.27 BI 213; MONOCLONAL ANTIBODY C595; MONOCLONAL ANTIBODY CD20 BI 213; MONOCLONAL ANTIBODY M 195 AC 225; MONOCLONAL ANTIBODY M 195 BI 213; MONOCLONAL ANTIBODY MX35 AT 211; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 2 BI 213; RADIUM; RADIUM 223; UNCLASSIFIED DRUG; YTTRIUM 90; RADIOISOTOPE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER THERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OLIGODENDROGLIOMA; PANCREAS CANCER; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TUMOR REGRESSION; ALPHA RADIATION; METHODOLOGY; NEOPLASM; RADIOTHERAPY; REVIEW; TREATMENT OUTCOME;

ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 54049137660     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488708785700339     Document Type: Article

References (27)

1. Workshop on alpha emitting radionuclides in therapy. Aachen, Germany 2007; April 28-29.
2. Allen BJ. Can alpha-immunotherapy succeed where other systemic modalities have failed? Nucl Med Commun 1999; 20: 205-7.
3. Allen BJ. Internal high LET targeted radiotherapy for cancer. Phy Med Biol 2006; 51: R327-41.
4. Zalutsky MR. Current status of therapy of solid tumours: brain tumour therapy. J Nucl Med 2005; 46: 151S-6S.
5. 213Bi, and their decay chain realted radionuclides, for therapeutic applications. Chem Rev 2001; 101: 2019-36.
6. Jurcic GJ, Larson SM, Sgouros G, et al. Targeted alpha-particle immunotherapy for myeloid leukaemia. Blood 2002; 100: 1233-9.
7. Allen BJ, Rizvi, SM & Tian Z. Preclinical targeted alpha therapy for subcutaneous melanoma. Melanoma Res 2001; 11: 175-82.
8. Allen BJ, Raja C, Rizvi SMA, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2005; 4: 1318-24.
9. Raja C, Graham P, Rizvi SMA, et al. Interim analysis of toxicity and response in Phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2007; 6(6): 846-52.
10. Nilsson S, Larsen RH, Fosså SD, et al. First Clinical Experience with alpha-Emitting Radium-223 in the Treatment of Skeletal Metastases Clinical Cancer Res 2005; 11: 4451-9.
11. Nilsson S, Tranzen L, Parker C, et al. Bone-targeted radium-233 in symptomatic, hormone refractory prostatwe cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-94.
12. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Sustance - P receptors inn human primary neoploasms: tumoral and vascular localization. Int J Cancer 1995; 61: 786-92.
13. Kneifel S, Corsier D, Good S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin Cancer Res 2006; 12(12): 3843-50.
14. Maecke HR. Radiolabeled peptides in nuclear oncology: influence of pepide structure and labeling strategy on pharmacology. Ernst Schering Res Found Workshop 2005; 43-72.
15. Schmidt D, Neumann F, Antke C, et al. Phase 1 clinical study on alpha-therapy for non-Hodgkin lymphoma. In 4th Alpla-Immunotherapy Symposium. Morgenstern A, Ed. ITU: Dusseldorf, Germany 2004; pp. 12.
16. Song BY, Rizvi SMA, Raja C, et al. The cytokinesis-block assay as a biological dosimeter for targeted alpha therapy. Phys Med Biol 2008; 53: 319-28.
17. 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin Exp Metastasis 2005; 22: 575-86.
18. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made of tandem repeats. J Biol Chem 1988; 263: 12820-3.
19. Price MR, Pugh JA, Hudecz F, et al. C595-A monoclonal antibody against the protein core of the humanurinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer 1990; 61: 681-6.
20. 213Bi-C595 radioimmunoconjugate. Brit J Cancer 2004; 91: 2086-93.
21. Li Y, Rizvi SMA, Brown J, et al. Antigenic expression of human prostate cancer cell lines and primary prostate cancer sections for in vitro multiple targeted alpha therapy with Bi-213 conjugates. Int J Radiat Oncol Biol Phys 2004; 60/3: 896-8.
22. 213Bi-labelled PAI2 in preclinical targeted alpha therapy of cancer. Cancer Biol Ther 2007; 6(6): 898-904.
23. Allen BJ, Baja C, Rizvi SMA, Song EY, Graham P. Tumour antivascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys Med Biol 2007; 52: L15-9.
24. Dadachova E, Nakouzi A, Bryan R, Casadevall A. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci USA 2003; 100: 10942-7.
25. Dadachova E, Howell RW, Bryan RA, et al. Susceptibility of human pathogens Cryptococcus neoformans and Histoplasma capsulateum to gamma radiation versus radioimmunotherapy with alpha and beta-emitting radioisotopes. J Nucl Med 2004; 45:313-20.
26. Dadachova E, Burns T, Bryan RA, et al. Feasibility of radioimmunotherapy of experimental pneumoccal infection. Antimicrob Agents Chemother 2004; 48: 1624-9.
27. Dadachova B, Patel MC, Toussi S, et al. Targeted killing of virally infected cells by radiolabelled antibodies to viral proteins. PLoS Med 2006; 2(11): e427.